Altered Regional Homogeneity and Functional Connectivity during Microlesion Period after Deep Brain Stimulation in Parkinson’s Disease

Table 1

Demographic and clinical data of all subjects.

	HCs (n = 12), mean ± SD	PD (n = 27), mean ± SD	value
Age (years)	63.92 ± 8.38	62.30 ± 8.97	0.60^a
Sex (male/female)	6/6	16/11	0.59^b
Disease duration (year)	NA	8.26 ± 2.78	—
LEDD (mg/d)	NA	765.78 ± 176.74	—
HAMA score	0.42 ± 0.51	5.59 ± 3.71	<0.001^a
HAMD score	0.75 ± 0.87	5.63 ± 3.95	<0.001^a
PDQ-39 score	NA	42.96 ± 16.97	—
MoCA score
Before DBS	28.67 ± 1.07	24.22 ± 3.94	<0.001^a
One day after DBS	NA	21.82 ± 4.78	—
One month after DBS	NA	23.78 ± 3.81	0.001^c
UPDRS-III score
Before DBS	NA	37.70 ± 12.04	—
One day after DBS	NA	27.52 ± 6.98	—
One month after DBS	NA	38.70 ± 10.89	<0.001^c
VF score
Before DBS	NA	20.63 ± 4.51	—
One day after DBS	NA	13.85 ± 4.10	—
One month after DBS	NA	16.30 ± 4.03	<0.001^c
BJLOT score
Before DBS	NA	21.30 ± 2.74	—
One day after DBS	NA	16.85 ± 3.21	—
One month after DBS	NA	19.48 ± 2.83	<0.001^c
TMT-A score
Before DBS	NA	45.70 ± 12.08	—
One day after DBS	NA	52.89 ± 11.62	—
One month after DBS	NA	49.96 ± 11.33	<0.001^c
TMT-B score
Before DBS	NA	99.07 ± 10.96	—
One day after DBS	NA	109.22 ± 10.93	—
One month after DBS	NA	103.74 ± 11.06	<0.001^c

HCs, healthy controls; PD, Parkinson’s disease; LEDD, levodopa equivalent daily dose; MoCA, Montreal cognitive assessment; HAMA, Hamilton anxiety scale; HAMD, Hamilton depression scale; UPDRS-III, the unified Parkinson’s disease rating scale part-III; PDQ-39, the 39-item Parkinson’s disease questionnaire; VF, verbal fluency; BJLOT, Benton judgment of line orientation test; TMT-A/B, trail making test part A/B; NA, not applicable; DBS, deep brain stimulation; SD, standard deviation. ^a value was obtained by a two-sample t-test between PD and HCs groups. ^b value was obtained by a chi-square test between PD and HCs groups. ^cvalue was obtained by a repeated measures ANOVA test in three sessions. .